Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Sionna Therapeutics, Inc.NASDAQ: SION
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $6.55M rose 212.9% year over year, behind the +220.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 71.3% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +212.9% toward the trailing-twelve-month pace of +220.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 12.07M USD
- Year-over-year change
- +225.4%
- 3-year CAGR
- +92.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.07M | +225.4% |
| FY2024 | 2024-12-31 | 3.71M | +64.1% |
| FY2023 | 2023-12-31 | 2.26M | +34.0% |
| FY2022 | 2022-12-31 | 1.69M | — |
Stock-Based Compensation vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 stock-based compensation of $16.53M is the smallest of the 11 companies compared; the peer median is $38.36M.
- Its year-over-year change of +220.6% is the highest of 11, against a peer median of +18.9%.
- Over three fiscal years its annual growth of +92.7% compares with a peer median of +34.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $85.94M | -13.0% | -16.6% | — | |
| LTM Mar 2026 | $51.03M | +21.9% | +65.8% | 11.9% | |
| LTM Jun 2026 | $49.78M | +71.5% | +62.2% | — | |
| LTM Sep 2026 | $48.87M | -15.9% | +4.1% | 72.0% | |
| LTM Mar 2026 | $38.79M | +1.8% | +32.7% | 179.5% | |
| LTM Sep 2026 | $37.94M | +56.7% | +91.1% | 14.3% | |
| LTM Sep 2026 | $37.41M | +60.8% | +68.9% | — | |
| LTM Sep 2026 | $36.81M | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $22.06M | +15.9% | +22.5% | 7.0% | |
| LTM Mar 2026 | $20.28M | +92.0% | +34.5% | 101.4% | |
| LTM Mar 2026 | $16.53M | +220.6% | +92.7% | — | |
| Peer median (excluding SION) | $38.36M | +18.9% | +34.5% | 72.0% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.